Last updated: May 26, 2026
Suppliers for amitriptyline hydrochloride + perphenazine split into two tiers: API makers (amitriptyline HCl; perphenazine) and finished-dose / combo product suppliers (tablets) that source those APIs. The supplier landscape is mostly driven by the API global market because combination products often come from different finished-goods manufacturers across regions.
This overview enumerates the supplier categories and the practical vendor pathways used in procurement, licensing, and supply-risk review.
Who supplies amitriptyline hydrochloride API for combination products?
Featured snippet answer: Amitriptyline HCl API supply is concentrated among multinational generics/API specialists and Indian and Chinese API manufacturers with broad export footprints.
Common supplier archetypes
-
API-focused manufacturers
- Produce amitriptyline hydrochloride as a standalone API for generic tablets and combination products.
- Usually support DMF/CEP pathways and offer multiple particle-size, polymorph, and impurity specifications depending on customer brief.
-
Integrated generics companies
- Manufacture API internally for their own finished-dose products.
- Also sell API through commercial channels or through captive group entities.
-
Distributors and trading houses
- Stock and broker amitriptyline HCl from API producers.
- Useful when qualification timelines must compress, but increases traceability and audit scope complexity.
What procurement typically specifies for amitriptyline HCl
- Assay/purity and impurity profile (process-related impurities, including halogenated and related amine impurities)
- Crystal form / polymorph compliance if the customer specifies an internal equivalency
- Water content and particle size
- Solvent residuals limits aligned to ICH Q3C
- Stability for powder storage and conversion into tablet blend
Who supplies perphenazine API for combination products?
Featured snippet answer: Perphenazine API is supplied by a smaller set of API producers than many CNS APIs, but vendor coverage is still broad through Indian and Chinese API manufacturers and through integrators that also sell tablets.
Typical perphenazine API supplier structure
- Specialty antipsychotic API plants
- Produce perphenazine as an API with controlled impurities and consistent particle characteristics.
- Generic producers with captive API
- Use perphenazine API for their own finished formulations; some sell excess API.
- International distributors
- Provide perphenazine API from multiple sources with batch documentation and import support.
Perphenazine-specific quality checkpoints
- Impurity set for phenothiazine-related contaminants
- Salt/hydrochloride identity (perphenazine itself is typically the free base; specifications depend on the customer’s finished product target)
- Residual solvents and heavy metal controls
- Analytical method validation expectations at customer qualification
Which companies supply the finished-dose amitriptyline + perphenazine combination tablets?
Featured snippet answer: Finished-dose supply for amitriptyline hydrochloride + perphenazine combinations comes from generics manufacturers and local brands, with country-specific label holders. The most reliable supplier mapping is by NDC (US), national registration number (EU/UK), or local marketing authorization linked to the product’s composition.
Finished-dose supply channels
- Marketing authorization holder (MAH) / brand owner
- Owns the regulatory file and controls labeling, batch release, and ongoing lifecycle filings.
- Contract manufacturers (CMO)
- Produce tablets under GMP with the MAH’s specifications.
- Parallel distributors
- Import from the MAH’s approved markets; not always suitable for new projects due to document access limits.
What buyers typically request for combo-tablet qualification
- GMP site and batch history
- CoA and impurity trends for both actives
- Bio-relevant dissolution method and in-house specs
- Stability protocol for the market’s shelf-life requirement
How do procurement teams identify reliable suppliers for amitriptyline HCl + perphenazine?
Featured snippet answer: Teams qualify via a document package that traces from API supplier to tablet batch release, aligned with ICH Q7/Q8/Q9 and cGMP expectations.
Standard supplier qualification stack
- Facility qualification
- GMP certificate, quality agreement readiness, audit outcomes
- DMF/CEP alignment
- Confirms regulatory standing of the API source
- CoA and CoC
- Batch-by-batch documentation for identity, assay, and impurities
- Analytical verification
- Independent identity testing and impurity confirmation using agreed methods
- Change management
- Notification of process changes, site transfers, and impurity specification revisions
Supply-risk checks specific to CNS combinations
- Single-site dependency
- If both APIs come from the same geographic cluster, disruption risk increases
- Impurity drift across API batches
- A common delay driver when customers use tight impurity specs
- Regulatory file ownership
- Some projects stall if API DMFs are not cross-referenced for the customer’s target market
What patent/IP barriers affect alternative sourcing of amitriptyline + perphenazine?
Featured snippet answer: For established small-molecule combinations, IP barriers in many jurisdictions are typically dominated by product/formulation and method-of-use remnants, not the base APIs. The commercial and regulatory risk is usually governed by regulatory exclusivity and product-specific patents, not by general availability of amitriptyline or perphenazine APIs.
Where IP risk typically sits
- Tablet formulation patents
- Release profile, excipient systems, compression characteristics
- Process patents
- Specific synthesis or purification steps
- Method-of-use patents
- Indications, dosing regimens, or patient subsets
Practical supplier impact
- Suppliers of API may remain interchangeable, while finished-dose suppliers must navigate product patent status in each country.
What regulatory pathways govern combo products containing amitriptyline HCl + perphenazine?
Featured snippet answer: In most markets, the combo tablets are approved under generic or hybrid approval routes that require comparability to an approved reference product and chemistry manufacturing controls.
Typical regulatory elements buyers validate
- MAA/ANDAs for generics
- Bioequivalence package when required
- Stability data covering storage conditions for shelf-life
- GMP compliance for tablet manufacturing site and API sources
Supplier landscape by geography: where do vendors typically cluster?
Featured snippet answer: For these older CNS active ingredients, API manufacturing clusters remain concentrated in India and China, with finished-dose supply and local registrations in US/EU/UK and additional regulated markets.
Procurement approach by region
- US projects: rely on suppliers that can support DMF referencing and US-facing regulatory packages for API and finished dose
- EU projects: prioritize CEP-aligned API where available and GMP-ready CMO documentation
- Emerging markets: qualification can rely more on CoA and GMP certifications, but product stability and dissolution alignment still drive launch timelines
What finished-dose and API documentation should suppliers provide?
Featured snippet answer: Buyers typically require full traceability from API CoA to finished-dose CoA, plus a change-control and stability dossier.
API documentation set
- CoA: identity, assay, impurities, water/LOD
- Specification sheet
- Batch manufacturing record summaries if requested under quality agreement
- Stability summary for API
- GMP certificate and audit report access
Finished-dose documentation set
- GMP batch release testing
- Dissolution profile and method
- Stability protocol and ongoing stability reports
- Packaging configuration documentation
Key takeaways
- Supplier coverage for amitriptyline hydrochloride and perphenazine is strongest at the API level, with many finished-dose manufacturers sourcing from qualified API producers.
- Procurement success hinges on document traceability, impurity/spec alignment, and change-control discipline more than on brand identity of the supplier.
- IP risk for combo products is typically product/formulation-specific rather than a barrier to the standalone APIs, which keeps API sourcing broad but finished-dose sourcing more constrained by local regulatory status.
FAQs
1) Can I source amitriptyline hydrochloride and perphenazine APIs from different suppliers for the same combo tablet project?
Yes, if both API sources are qualified under the same specification regime, and quality agreements cover impurity and change-control.
2) What is the main reason combo product sourcing delays occur for amitriptyline + perphenazine?
API impurity drift and mismatch to the target finished-dose specification, followed by dissolution and stability alignment work.
3) Are perphenazine and amitriptyline hydrochloride APIs widely available globally?
Yes, through multiple API producers and distributors, though the number of qualified options can vary by market acceptance of DMF/CEP and supported documentation.
4) Do finished-dose combo products require the same supplier as the APIs?
No. The finished-dose manufacturer can source APIs from different qualified API suppliers as long as it maintains traceability and regulatory compliance.
5) What vendor due diligence matters most for CNS actives in combination tablets?
Impurity control, analytical method transfer readiness, GMP and audit outcomes for both API and tablet sites, and a robust change notification process.
References
No sources were provided in the prompt, and no supplier-specific company list or regulatory record (Orange Book, EMA register, or national databases) was supplied. As a result, no citations can be provided without introducing non-cited claims.
